Page 621 - Read Online
P. 621
Page 6 of 11 Ichida et al. Hepatoma Res 2020;6:54 I http://dx.doi.org/10.20517/2394-5079.2020.59
Figure 1. Overall survival (A) and recurrence rate (B) of patients meeting each indication criteria. DEC: double eligibility criteria
despite the potential of a live donor, and there has been strong demands to expand insurance coverage for
those beyond the Milan criteria. When establishing government-approved expanded criteria, achieving
a 5-year recurrence rate of less than 10% and a 5-year survival rate of over 70% seems reasonable and
[29]
socially acceptable in the setting of LDLT for HCC , which was achieved in the benchmark study by
